Jiedu Yizhi Formula Improves Cognitive Function by Regulating the Gut Dysbiosis and TLR4/NF-κB Signaling Pathway

Abstract

Objective The objective of this study was to explore the neuroprotective mechanism of JDYZF in treating AD from the perspective of inflammation and intestinal microflora. Methods A total of 24 APP/PS1 mice were randomly divided into four groups: model (n = 6), JDYZF low-dose (n = 6), JDYZF high-dose (n = 6), and positive drug (n = 6), six C57 mice were used as the control group. The body weights and diets of all mice were examined daily. After 8 weeks of administration, the learning and memory of mice were evaluated by the Morris water maze test. The histopathological changes of hippocampus, liver and kidney in mice were observed by HE staining after being euthanized. The expression of p-tau in hippocampus tissue was detected by immunohistochemistry. After that, 16S rDNA sequencing was used to investigate the relationship between JDYZF and intestinal microbiota. Finally, a comparison of TLR4, p65, p-p65, iκB, p-iκB, and IL-1β protein expression in the hippocampus tissue of mice in each group was measured by Western blot. Results The results showed that APP/PS1 mice taking JDYZF orally were generally in good condition. Compared with the control group, JDYZF significantly improved learning and memory ability in ethology. Histology showed that JDYZF improved the hippocampal structure of mice and inhibited the deposition of p-tau. JDYZF treatment could regulate the gut microbiota of APP/PS1 mice by increasing the richness of Lachnospiraceae, Ruminococcaceae , and Actinobacteria and reducing that of Alistipes and Muribaculaceae . It also significantly inhibited the activation of the TLR4/NF-κB signaling pathway in the brain. In addition, no obvious toxic reactions were found in the liver and kidney of APP/PS1 mice after taking JDYZF for 8 weeks. Conclusion The findings revealed that JDYZF improved cognitive ability and alleviated the TLR4/NF-κB signaling pathway in APP/PS1 mice, and the modulating the gut microbiota presented here may help illuminate its activation mechanism.

Herbal medicines in Alzheimer’s disease and the involvement of gut microbiota

“…In a pig model, CM could modulate the intestinal barrier function by improving intestinal morphology, elevating the expression of zona occluden-1, claudin-1, down-regulating pro-inflammatory cytokines and up-regulating anti-inflammatory cytokines due to its effect on suppressing the expression of key proteins of the TLR4/NF-κB signaling pathway. It also changed the gut microbial composition and increased the levels of acetate and butyrate ( Zhang P. et al, 2023 ). The modulatory effects of cordycepin on gut microbiota and metabolites may be one of the specific mechanisms influencing AD progression, which still needs to be further confirmed.…”

ApoE Mimetic Peptides to Improve the Vicious Cycle of Malnutrition and Enteric Infections by Targeting the Intestinal and Blood-Brain Barriers

“…There is great concern about the clinical relevance of studying the intestinal microbiota in patients with AD. Some studies showed that changes in intestinal microbial composition were associated with cognition, especially memory [108,109], while others collected important clinical characteristics, such as educational level, APOE genetic background, cognitive function, and illness severity. The occurrence of the genera Saccharimonadales, Patescibacteria and Saccharimonadia was found to be related to aging.…”

Neuroprotective Mechanisms and Metabolomics Analysis of Jiedu Yizhi Formula in Alzheimer's Disease

“…JDYZF is composed of seven traditional Chinese medicines, which were obtained from the same source and were subjected to rigorous quality control measures. It has been demonstrated that JDYZF exerts an impact on the brains of APP/PS1 transgenic mice by reducing the neuroin ammatory response and decreasing the deposition of Aβ through the regulation of the brain TLR4/NF-κB pathway (Zhang et al 2023). The group conducted an experiment where they extracted polysaccharides from Coptis chinensis Franch(CCF), the primary drug in the formula under investigation.…”